This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Data Demonstrating In Vitro Potency Of Dalbavancin Against Bacterial Pathogens Presented At The 23rd Annual ECCMID Meeting

CHICAGO, April 29, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced data from surveillance results of its lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSSI). The data, presented at the 23 rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), demonstrate that in vitro potency of dalbavancin remains consistent with earlier surveillance reports.

Dalbavancin Activity in the USA: Reported from the SENTRY Programme (2012) Authors: R.N. Jones, R.K. Flamm, H.S. Sader, B.P. Goldstein, M. Dunne (North Liberty, Morristown, US) Poster #: P1646

Study conclusions: Year 2012 SENTRY Program surveillance results for dalbavancin (DAL) document sustained potent activity against SA, CoNS, βHS, VGS and VAN-S enterococci, that averaged four to 32-fold greater than VAN, DAP or LZD. Further development of DAL appears warranted from these in vitro potency results for an antibiotic requiring very infrequent dosing.

Further Study Details

Dalbavancin potency was assessed in the 2012 SENTRY Antimicrobial Surveillance Program among 1,589 isolates sampled from the nine USA Census regions (27 medical centers) to update the 38,813 organism collections reported for 2006-2011 (2011 and 2012 ICAAC). Researchers monitored Gram-positive cocci included Staphylococcus aureus (SA; 1,000/50% MRSA), coagulase-negative staphylococci (CoNS; 122); Enterococcus faecalis (30); E. faecium (30); Streptococcus pyogenes (151); S. agalactiae (134; 336 β-haemolytic streptococci overall) and viridans group streptococci (VGS; 71). All susceptibility (S) testing used CLSI reference broth microdilution methods and EUCAST interpretations for comparison agents.

Surveillance data showed that dalbavancin (MIC 50/90, 0.06/0.06 mg/L) was eight to 16-fold more active than daptomycin (DAP), linezolid (LZD) and vancomycin (VAN), against SA; with MSSA and MRSA having the same MIC 90 results. CoNS was equally DAL-S (MIC 90, 0.06 mg/L). The highest staphylococcal DAL MIC was only 0.25 mg/L as it was in 2011. β-haemolytic streptococci (βHS) and VGS had DAL MIC values ranging from <=0.03 to 0.25 mg/L (MIC 90, <=0.03-0.06 mg/L) and only enterococci showed elevated DAL MIC results. VanA phenotype-resistant E. faecalis or E. faecium had non-S DAL MIC values (>=4 mg/L). VanB resistance strains were DAL-S (MIC, <=0.12 mg/L).

All cited DAL quantitative values were totally consistent with earlier surveillance data (2006-2011), without evidence of MIC creep. LZD-R CoNS was detected (modified target mechanism).
  Cum. % inhibited at DAL MIC (µg/ml):
Organism (no.) ≤ 0.03 0.06 0.12 0.25 0.5 1 ≥ 2
S. aureus              
MSSA (500) 21.6 91.6 100.0 -- -- --* --
MRSA (500) 16.8 90.0 99.8 100.0 -- --* --
CoNS (122) 49.2 91.8 99.2 100.0 -- -- --*
βHS (336) 91.7 97.9 99.1 100.0 --* -- --
VGS (71) 84.5 98.6 100.0 -- -- --* --
Van-susceptible (33) 0.0 66.7 93.9  100.0 -- --* --
VanA (25) 0.0 0.0 0.0 4.2 4.2 12.5 100.0
VanB(2) 50.0 0.0 100.0 -- -- -- --
*=vancomycin MIC 90

A copy of this poster is available on Durata's website: .

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient's hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 0.00%
FB $117.43 0.00%
GOOG $692.36 0.00%
TSLA $232.32 0.00%
YHOO $36.01 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs